文献速递中毒与环境急症消化、代谢与肾脏急症

缓释纳曲酮与丁丙诺啡-纳洛酮预防阿片类复发的比较效果(X:BOT):一项多中心、开放标签、随机对照试验

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
PubMed 文献 · Lancet · 2017-11-14
一句话结论在阿片类使用障碍患者中,缓释纳曲酮诱导成功率低于丁丙诺啡-纳洛酮,导致意向治疗人群复发更多,但成功诱导后两者安全有效相当。

X:BOT试验在美国8个社区住院服务点纳入570例18岁以上、符合DSM-5阿片类使用障碍且过去30天使用非处方阿片类的患者,1:1随机接受缓释纳曲酮(每月肌注)或丁丙诺啡-纳洛酮(每日舌下含服),随访24周。意向治疗人群中,缓释纳曲酮组24周复发事件185/283(65%)高于丁丙诺啡-纳洛酮组163/287(57%),HR 1.36(95%CI 1.10-1.68),差异主要归因于缓释纳曲酮诱导失败者的早期复发(79例诱导失败中70例早期复发)。成功诱导后(符合方案人群,n=474),两组24周复发事件相似(p=0.44)。除轻中度注射部位反应外,治疗中出现的不良事件包括过量两组无差异,共发生5例致死性过量(缓释纳曲酮组2例,丁丙诺啡-纳洛酮组3例)。

要点

  • 缓释纳曲酮诱导成功率72%(204/283)低于丁丙诺啡-纳洛酮94%(270/287),p<0.0001。
  • 意向治疗人群24周复发:缓释纳曲酮组65%(185/283)vs 丁丙诺啡-纳洛酮组57%(163/287),HR 1.36(95%CI 1.10-1.68)。
  • 差异主要来自缓释纳曲酮诱导失败者的早期复发:79例诱导失败中70例(89%)早期复发。
  • 成功诱导后(符合方案人群n=474),两组24周复发事件相似(p=0.44)。
  • 意向治疗人群中,丁丙诺啡-纳洛酮组阿片阴性尿样(p<0.0001)和阿片戒断天数(p<0.0001)优于缓释纳曲酮组;符合方案人群中两组相似。

适用人群与场景

  • 18岁及以上、符合DSM-5阿片类使用障碍、过去30天使用过非处方阿片类的患者。
  • 研究在美国8个社区住院服务点启动,随后门诊随访。

诊断标准与关键阈值

  • 复发定义:连续4周任何非研究阿片类使用(尿液毒理学或自我报告),或连续7天自我报告使用。

处置流程与药物剂量

  • 缓释纳曲酮:每月肌内注射(Vivitrol;Alkermes)。
  • 丁丙诺啡-纳洛酮:每日自我给药舌下含片(Suboxone;Indivior)。
  • 研究为期24周门诊治疗。

研究设计与关键结果

  • 多中心、开放标签、随机对照比较效果试验,纳入570例,随机1:1至缓释纳曲酮(n=283)或丁丙诺啡-纳洛酮(n=287)。
  • 缓释纳曲酮诱导成功204/283(72%),丁丙诺啡-纳洛酮诱导成功270/287(94%),p<0.0001。
  • 意向治疗人群24周复发事件:缓释纳曲酮组185/283(65%)vs 丁丙诺啡-纳洛酮组163/287(57%),HR 1.36(95%CI 1.10-1.68)。
  • 差异主要归因于缓释纳曲酮诱导失败者的早期复发:79例诱导失败中70例(89%)早期复发。
  • 符合方案人群(成功诱导,n=474)24周复发事件两组相似(p=0.44)。
  • 意向治疗人群中,阿片阴性尿样(p<0.0001)和阿片戒断天数(p<0.0001)有利于丁丙诺啡-纳洛酮组;符合方案人群中两组相似。
  • 自我报告的阿片渴求 initially 缓释纳曲酮组低于丁丙诺啡-纳洛酮组(p=0.0012),至第24周趋同(p=0.20)。
  • 除轻中度缓释纳曲酮注射部位反应外,治疗中出现的不良事件包括过量两组无差异;发生5例致死性过量(缓释纳曲酮组2例,丁丙诺啡-纳洛酮组3例)。

证据类型、等级与局限

  • 研究类型:多中心、开放标签、随机对照比较效果试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在该人群中缓释纳曲酮比丁丙诺啡-纳洛酮更难启动,这对总体复发产生了负面影响。
  • 作者认为,一旦成功启动,两种药物同样安全有效。
  • 作者建议,未来工作应侧重于促进缓释纳曲酮的诱导启动以及改善两种药物的治疗保留。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Extended-release naltrexone (XR-NTX), an opioid antagonist, and sublingual buprenorphine-naloxone (BUP-NX), a partial opioid agonist, are pharmacologically and conceptually distinct interventions to prevent opioid relapse. We aimed to estimate the difference in opioid relapse-free survival between XR-NTX and BUP-NX.

METHODS: We initiated this 24 week, open-label, randomised controlled, comparative effectiveness trial at eight US community-based inpatient services and followed up participants as outpatients. Participants were 18 years or older, had Diagnostic and Statistical Manual of Mental Disorders-5 opioid use disorder, and had used non-prescribed opioids in the past 30 days. We stratified participants by treatment site and opioid use severity and used a web-based permuted block design with random equally weighted block sizes of four and six for randomisation (1:1) to receive XR-NTX or BUP-NX. XR-NTX was monthly intramuscular injections (Vivitrol; Alkermes) and BUP-NX was daily self-administered buprenorphine-naloxone sublingual film (Suboxone; Indivior). The primary outcome was opioid relapse-free survival during 24 weeks of outpatient treatment. Relapse was 4 consecutive weeks of any non-study opioid use by urine toxicology or self-report, or 7 consecutive days of self-reported use. This trial is registered with ClinicalTrials.gov, NCT02032433.

FINDINGS: Between Jan 30, 2014, and May 25, 2016, we randomly assigned 570 participants to receive XR-NTX (n=283) or BUP-NX (n=287). The last follow-up visit was Jan 31, 2017. As expected, XR-NTX had a substantial induction hurdle: fewer participants successfully initiated XR-NTX (204 [72%] of 283) than BUP-NX (270 [94%] of 287; p<0·0001). Among all participants who were randomly assigned (intention-to-treat population, n=570) 24 week relapse events were greater for XR-NTX (185 [65%] of 283) than for BUP-NX (163 [57%] of 287; hazard ratio [HR] 1·36, 95% CI 1·10-1·68), most or all of this difference accounted for by early relapse in nearly all (70 [89%] of 79) XR-NTX induction failures. Among participants successfully inducted (per-protocol population, n=474), 24 week relapse events were similar across study groups (p=0·44). Opioid-negative urine samples (p<0·0001) and opioid-abstinent days (p<0·0001) favoured BUP-NX compared with XR-NTX among the intention-to-treat population, but were similar across study groups among the per-protocol population. Self-reported opioid craving was initially less with XR-NTX than with BUP-NX (p=0·0012), then converged by week 24 (p=0·20). With the exception of mild-to-moderate XR-NTX injection site reactions, treatment-emergent adverse events including overdose did not differ between treatment groups. Five fatal overdoses occurred (two in the XR-NTX group and three in the BUP-NX group).

INTERPRETATION: In this population it is more difficult to initiate patients to XR-NTX than BUP-NX, and this negatively affected overall relapse. However, once initiated, both medications were equally safe and effective. Future work should focus on facilitating induction to XR-NTX and on improving treatment retention for both medications.

FUNDING: NIDA Clinical Trials Network.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Lee JD, Nunes EV, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2017. PMID: 29150198. doi:10.1016/S0140-6736(17)32812-X

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。